Browse > Article
http://dx.doi.org/10.15616/BSL.2015.21.1.32

Human Papillomavirus Prevalence and Genotype Distribution in Normal and ASCUS Specimens: Comparison of a Reverse Blot Hybridization Assay with a DNA Chip Test  

Kim, Sunghyun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
Lee, In-soo (Department of Clinical Laboratory Science, Hyejeon College)
Lee, Dongsup (Department of Clinical Laboratory Science, Hyejeon College)
Abstract
High-risk (HR) human papillomavirus (HPV) genotypes are strongly associated with cervical cancer, whereas other HPV genotypes are not. To identify the various HPV genotypes in clinical samples, we conducted HPV genotyping using a DNA chip test and reverse blot hybridization assay (REBA) in normal cytology samples and atypical squamous cells of undetermined significance (ASCUS) cytology samples. We also investigated the HPV infection rate and HPV genotype prevalence in women with normal cytology and ASCUS cytology. Liquid-based cytology preparations were used for the initial screening of 205 subjects with normal cytology and ASCUS cytology. The HPV infection rate was 49.8% when using the DNA chip assay and 61.0% when using the REBA test. In patients with normal cytology, the HR-HPV positive rate was 21.9% with the DNA chip assay and 43.9% with the REBA test. In contrast, 8.3% of patients with ASCUS were HR-HPV positive when using the DNA chip assay, and 13.6% were positive when tested with the REBA test. The infection rate of HR-HPV in the 40~50-year age group was significantly higher than that of the other age groups. Based on the cytological analysis of the normal and ASCUS samples, the five most prominent HPV genotypes were HPV 16, 18, 68, 33, and 58 using the DNA chip test, and they were HPV 16, 18, 53, 33, and 66 when using the REBA test. In conclusion, the findings show that the results of the REBA test are comparable to those of the DNA chip test. Most strikingly, the REBA test detected the HR-HPV genotype associated with cervical carcinoma similar to that detected with the DNA chip method. Therefore, the REBA test is a useful method to detect clinically important HR-HPV genotypes.
Keywords
Human papillomavirus; Uterine cervix cancer; DNA chip; Reverse blot hybridization assay;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol. 2009. 81: 529-535.   DOI
2 Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995. 87: 796-802.   DOI
3 Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, Vellone VG, Durante M, Fadda G, Scambia G, Capelli G, De Vincenzo R. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol. 2009. 47: 3895-3901.   DOI
4 Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003. 88: 63-73.   DOI
5 de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007. 7: 453-459.   DOI
6 Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989. 243: 934-937.   DOI
7 Gaarenstroom KN, Melkert P, Walboomers JM, Van Den Brule AJ, Van Bommel PF, Meyer CJ, Voorhorst FJ, Kenemans P, Helmerhorst TJ. Human papillomavirus DNA and genotypes:prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994. 4: 73-78.   DOI
8 Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995. 87: 1365-1371.   DOI
9 Hong SR, Kim IS, Kim DW, Kim MJ, Kim AR, Kim YO, Kim HS, Rha SH, Park GS, Park YK, Park YS, Park HS, Suh KS, Sohn JH, Shin MK, Oh HK, Yun KJ, Yoon HK, Lee SN, Lee AW, Lee HJ, Cho HY, Choi C, Jung WW. Prevalence and genotype distribution of cervical human papillomavirus DNA in Korean women: a multicenter study. Korean J Pathol. 2009. 43: 342-350.   DOI
10 Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006. 44: 1310-1317.   DOI
11 Kim YS, Lee HJ, Lee GG, Park SY, Lee GE, Suh JT, Huh JY. Detection of human papillomavirus type 16 and 18 in cervical specimens by nested polymerase chain reaction. Korean J Clin Pathol. 2001. 21: 210-214.
12 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003. 348: 518-527.   DOI
13 Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM. Comparison of PCRand hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998. 36: 3248-3254.
14 Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999. 83:870-873.   DOI
15 Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, Adami HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000. 355: 2194-2198.   DOI
16 Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990. 63: 1129-1236.   DOI
17 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015. E-pub.   DOI
18 Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer. 1998. 75: 536-545.   DOI
19 Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009. 19: 97-113.   DOI
20 zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000. 92: 690-698.   DOI